The US Food and Drug Administration has approved fitusiran for bleeding prophylaxis in hemophilia A and B with or without ...

Researchers identified patients with stage I-III TNBC diagnosed between 2010 and 2021 and assessed trends in NACT use, ...

The benefits of naltrexone/bupropion (Mysimba) continue to outweigh its risks, despite ongoing uncertainty about long-term ...

The EMA has recommended refusing marketing authorization for donanemab, a monoclonal antibody against amyloid beta, in the ...

Individuals testing positive for human papillomavirus (HPV) had a 40% greater risk for overall cardiovascular disease (CVD) ...

Pediatricians must disclose adverse events and medical errors to children and their families, according to an updated policy ...

Dr. Christopher J. Sayed shares insights on the growing emphasis on personalized care for hidradenitis suppurativa.

A retrospective study finds that low-dose doxycycline is as effective as high-dose for lymphocytic scarring alopecia while ...

DEA and HHS have delayed implementation of two rules for telehealth prescribing of buprenorphine until the end of the year to ...

A study published in Brain Communications revealed new insights into early detection of Alzheimer’s disease. Researchers have ...

In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...

The EMA’s Committee for Medicinal Products for Human Use said that a phase 3 study in children aged 3-14 years demonstrated ...